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CHAPTER 13 
Overview of FK506 in Transplantation 
John J. Fung, Kareem Abu-Elmagd, Satoru Todo, Ronald Shapiro, 
Andreas Tzakis, Mark Jordan, John Armitage, Ashok Jain, Mario Alessiani, 
Maureen Martin, Oscar Bronster, Andrei Stieber, Robert Kormos, Robert Selby, 
Robert Gordon, Donna Przepiorka, Elana Bloom, and Thomas E. Starzl 
Divisions of Transplantation Surgery. Cardiothoracic Surgery, Urologic Surgery, Hematology 
University of Pittsburgh School of Medicine, and Veterans Administration Medical Center 
Pittsburgh, Pennsylvania 
In 1987. Ochiai and coworkers reported on the 
qualities of a new immunosuppressive agent. FK506. 
Isolated from the fermentation broth of a SOil fungus. 
Streptomyces tsukubaensls (1). Extensive In vitro 
studies demonstrated its effectiveness In suppressing 
mixed lymphocyte cultures. presumably by inhibiting 1L2 
syntheSIS following alloactivation (2). The receptor for 
FK506 has been Identified and charactenzed as a pep-
tidyl-prolyl cis-trans isomerase (3). 
The background for the clinical development of 
FK506 has been well documented by Starzl (4). In vivo 
studies using a number of animal models have shown a 
marked ability to prevent rejection following various 
types of organ transplants (5-7). as weil as to prevent 
the development of graft-versus-host disease (GvHo) 
following bone marrow transplantation (8). More inter-
estingly. FK506 possesses the ability to reverse ongo-
ing rejection In animal models (7.9). as well as estab-
lished GvHD (10). This characteristic IS unique. for it is 
well known that cyclosporine (CsA) Will not reverse es-
tablished ongomg alloimmune responses. These 
properties continue to be evident during the clinical test-
ing of FK506. We will attempt to summarize the results 
of all human transplantation models in wnich FK506 has 
been utilized as either "rescue" therapy and/or "primary" 
therapy. including liver (11.12), kidney (13). heart (14). 




The trials in liver. kidney. heart. and bone marrow 
transplantation were conducted at the University of 
Pittsburgh. Presbyterian University Hospital. Children's 
Hospital of Pittsburgh, and the Veterans Administration 
Medical Center. with the approval of the respective In-
stitutional Review Boards. Informed consent was ob-
tained from patients or their appointed guardians. 
Patient Profiles 
In the liver study. patients were treated with FK506 
as part of 3 studies: a) rescue. In which 57 patients 
were entered for the diagnOSIs of acute rejection and 
116 were converted from CsA to FK506 for chrOniC 
rejection: b) 110 primary liver transplant reCipients who 
were treated with FK506 and lOw-dose steroids as the 
baseline immunosuppression following liver transplan-
tation: and c) a subsequent study involved a total of 81 
patients. prospectively randomized to either FK506 or 
CsA as the baseline immunosuppression following liver 
transplantation. 
In the kidney study. patients were treated with FK506 
as part of 2 studies: a) rescue. in which 21 patients 
were entered for the diagnosis of rejection: and b) 65 
primary kidney transplant recipients who were treated 
with FK506 and low-dose steroids as the baseline im-
munosuppression following transplantation. 
In the heart study. patients were also divided into 2 
groups: a) 30 patients were treated with FK506 as 
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pnmary Immunosuppression: and b) 10 patients were 
converted to FK506 because of persistent rejection. 
In the bone marrow study. 11 patients were entered 
as part of a rescue study and treated with FK506 for 
eVidence of perSistent manifestations of GvHD un-
responsive to conventional treatment protocols. 
Diagnostic Evaluations 
For patients who were experiencing organ dysfunc-
tion. the final categorization of dysfunction was based 
upon clinical. biochemical. and/or histopathologiC find-
ings. For all patients. either as primary or as rescue 
therapy. cause(s) of organ dysfunction were carefully 
looked for. the workup being customized to the organ or 
tissue transplanted. Ultrasonic determination of vessel 
patency and radiographic evaluation of the biliary or 
urinary systems were used to rule out technical or 
mechanical defects. Angiography was performed when 
Indicated. Appropnate Viral cultures and stains were 
used to detect wal infections. Protocol biopSies were 
utilized in the evaluation of efficacy of FK506 therapy. 
All biopSies were blinded and interpreted by a single 
experienced transplant pathologist (AJD). Biopsy 
specimens were fixed in neutral buffered formalin and 
routinely stained with hematoxylin and eosin. trichrome. 
and reticulin stains. The Criteria used for pathologiC 
diagnOSIs have been clearly defined In previous reports 
(15.16). 
Timing and Details of Therapy 
Initiation of FK506 treatment was done In the hospi-
tal and given Initially as a parenteral dose (0.075-0.15 
mg/kg. IV). continued until the pattent was able to ingest 
the oral form of FK506. generally at 0.3 mg/kg/day. In 2 
diVided doses. Dose adjustments of FK506 were based 
upon monitoring serum trough levels by ELISA (17) to 
achieve a 12-hour trough level between 1 -2 ng/ml and 
also according to clinical or biochemical parameters. 
Evaluation of Response 
Periodic determinations of liver and kidney functions 
were performed. Including total bilirubin. serum glutamiC 
transamtnases. SGOT and SGPT. alkaline phos-
phatase. blood urea nitrogen. and serum creatinine 
(Serl. All values are expressed as the value piuS/minus 
1 standard deViatIOn. Protocol biopSies were obtained 




In this population of 173 patients. many of whom 
were critically ill at the time of FK506 conversion. a total 
of 14 deaths were encountered (8.1 %). The causes of 
death were numerous. but the incidence of mortality 
was directly correlated with the medical condition of the 
patient at the time of FK506 conversion. Sepsis was 
the cause of death in 4 patients; 3 died of hemorrhagic 
complications: and 3 died of metastatic carcinoma fol· 
lowing transplantation. In 2 patients. retransplantation 
was not considered an option for the failing liver al-
lograft. One patient was started on FK50S with 
pathological findings of late chronic rejection and died 
of technical causes during an attempted retransplanta-
tlon. In 1 case. no cause of death could be determined: 
the patient died at home and FK506 had been discon-
tinued 4 months earlier. The biochemical response of 
the liver allografts to FK506 was analyzed by classifying 
patients into either acute or chronic relection. depend-
109 upon the principal histopathologic findings. Prior to 
FK506 therapy. the TBll. SGOT. and SGPT values for 
the 57 patients who were treated for acute rejection. 
documented on liver biopsy or as judged by biochemi-
cal and clinical parameters were: 4.68±5.91 mg/dl. 
240±431 lUll. and 292±383 lUll. respectively. These 
values fell by the sixth month to: O.7S±1.41 mg/dl. 
98±163 lUll. and 90±128 lUll. respectively. Patients 
with a presenting diagnOSIs of chronic rejection also had 
a beneficial response to FK506. For the 116 patients 
:reated for thiS speCific indication. the total bilirubin fell 
to normal values (pre-FK50S. 5.07±8.16 mg/dl; 6 
months. 0.99±1.47 mgldl) whereas the average trans-
aminase values were stili slightly elevated above nor-
mal values (pre-FK506. SGOT/SGPT. 200±175 
IU/1/275±223 lUll; 6 months. SGOT/SGPT. 44±72 
IU/V101±68 lUll). 
A Clinicopathologic study of the results of conversion 
of liver allografts from GsA to FK506 immunosuppres-
sion revealed that the biochemical improvement seen 
above was correlated with histopathologic Improvement 
(18). The biochemical Improvement In both acute and 
chronic rejection occurred earlier and in greater propor-
tion than the pathologic findings. Patients With acute 
rejection fared better than those with chrOniC rejection. 
With a higher response rate. In patients with chrOniC 
rejection. liver function studies and the degree of bile 
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patIents given esA. It is notewor-
thy that the incidence of cyto-
megalovirus infections did not ap-
pear to be increased when com-
pared to patients on esA. 
Prospective Randomized Study 
Based upon the encouraging 
results of the primary FK506 
series. a prospective. randomized 
study was initiated in patients un-[SO 
Savage p=O.388 Breslow p=O.407 
dergOing primary liver transplanta-
tion. which incorporated FK506 
and esA. along with steroids. After 
liver transplantation, 81 recipients 
were randomized to either FKS06 
(41 patients) or esA (40 patients). 
A single bolus of 1 gm of 
methylprednisolone followed by a 
daily dose of 20 mg of methylpred-
nisolone was the baseline steroid 
therapy for both groups. Biochemi-
cal and histopathologic parameters 
were monitored to determine the 
effectiveness of each therapy In 
40 
0 
ductular injury were signficantly worse among those 
who failed than those who responded. 
Primary Therapy 
Eight patients died. leaving an actual survival of 
92.7%. The follow-up penod was between 6 and 12 
months. When compared to 32S sequential liver 
transplants during the preceding year (prior to FKS06). 
the patient and graft survival results were statistically 
significantly better: 6-month survival was 79%. Of the 
8 deaths. S were due to sepsIs. 1 to heart failure. 1 to a 
cerebral vascular accident. and 1 to nonreversible 
hepatic coma. During the follow-up penod. SO% of all 
recipients were taken off sterOids and maintained on 
single-drug immunosuppression with FKS06. Yet 
S2.8% of all patients were rejection free during the en-
tire study period. The majority of rejection episodes 
were mild and easily controlled with a single dose of 
bolus steroids (either methylprednisolone or hydrocor-
tisone). Only 17.8% of the rejection episodes reqUired 
further steroid treatment In the form of a steroid taper or 
additional steroid boluses. In addition. only 11 .2% of 
the patients reqUired OKT3. The Incidence of serious 
infections. In spite of FKS06 potency. has not appeared 
to be alarming. The incidence of senous Infections was 
about SO% less than seen With an historical group of 
preventing rejection. Rejection 
episodes were treated with a single bolus of 1 gm of 
methylprednisolone. If this treatment failed to reverse 
the rejection episode. a total of SO mg of OKT3 was 
administered. The esA patients who failed to respond 
to therapy were converted to FKS06. in attempts to res-
cue the dysfunctional grafts. With the ability to rescue 
CsA-randomlzed dysfunctIOnal grafts With FKS06. 
patient and graft survival were essentially the same. 
Figure 1 shows the patient survival curves for the 2 
treatment groups. The 3-month patient survival for the 
2 groups was 100% for the FKS06 patients and 9S.6% 
for the esA group. The 6-month figures for patient sur-
vival were 94.7% and 88.8%. respectively. Figure 2 
demonstrates the corresponding graft survival curves 
for these patients. Three-month graft survival was 
93.4% for the FKS06 group versus 84.8% for the esA 
group. The corresponding 6-month figures were 93.4% 
and 78.1%. 
One measure of the effectiveness of a baseline im-
munosuppressive regimen is the rejection-free rate fol-
lowing transplantation. Since liver allograft rejection 
was strictly defined biochemically. histologically. and/or 
clinically. this parameter was a simple. objective 
endpoint. Figure 3 shows the percentage of patients in 
each group who remained rejection-free. In both 
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Figure 2. The corresponding graft survival curves for the 
GsA- and FK506-randomized patients are shown. The 
3-month graft survival for the 2 groups was 93.4% for the 
FK506 versus 84.8% fotthe GsA group. The 
corresponding 6-month figures were 93.4% and 78.1%. 
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Figure 3. Relative frequency of patients who are free of 
rejection is plotted against time following liver transplant. 
groups, the major incidence of 
rejection episodes occurred within 
the first 30 days: a mean day of 
21.S in the FK506 group. for the 
first rejection contrasted with a 
mean of 9.9 days In the GsA group 
(p<0.005). In addition. a statistical-
ly Significantly larger number of 
patients In the FKS06 group 
remained rejection free during the 
follow-up period (p<0.02S). At 1 
month, the rejection·free rate for 
the FKS06 patients was 61 %. while 
the GsA value was 18.1 % 
(p<O.001). There were few late 
rejections: 3 in the FKS06 group 
over the next 6 months. with 1 ad-
ditional late rejection in the GsA 
group. 
These results are In agreement 
With the original prrmary therapy 
group when compared With the his-
torical GsA experrence. The major 
benefit of a prospective ran· 
domized trial is to evaluate other 
surrogate parameters. The need 
for insulin therapy and the Infec· 
tious disease profiles between the 
2 groups were essentially the 
same. Renal function in both 
groups was assessed by the reo 
qUlrement for hemodialysis and the 
monthly SGr determinations. 
HemodialysIs was Initiated In 6 
CsA patients while stili on GsA. 
whereas 3 other GsA patients re-
qUired hemodialysIs dUring the 
conversion perrod to FK506. In the 
FKS06·randomized group. 4 
patients were dialyzed during the 
posttransplant perrod. The com· 
parative inCidence for hemodialysIs 
requirement between the FK506 
and GsA groups (excluding ter· 
mlnal hemodialysis) was 10% and 
21.6%. respectively. Long-term 
hemodialysis (after 3 months 
posnransplant) was only required 
in 1 patient In each group. During 
the first 4 months. there was linle 
appreciable difference in the SGr 
for the 3 groups with functlomng kidneys.The severity of 
hypertension was assessed by the need for antihyper-
tensive medications follOWing transplantation. The In-
cidence of hypertension In the overall CsA-randomlzea 
group was 52.9% versus 26.9% for the FK506-treated 
group (p<0.01). at 3 months posttransplant. The in-
cidence of hypertension In the 14 patients who were on 




A total of 21 patients were converted from CsA-
based immunosuppression to FK506-based im-
munosuppression for persistent kidney rejection. No 
deaths were encountered. Of the 21 patients. 10 were 
classified as late rejection episodes (>60 days), while 
11 were treated early in the posttransplant course « 60 
dayS). Seven of the 11 early rescues were successful. 
In contrast to only 4 of 1 0 late rescues. Most of the 
FK506 failures were In patients who had chromc 
glomerulosclerosis and chromc rejection on biopsy. 
prior to FK506 rescue. The results were better in those 
patients with acute cellular reJection. The SCr at con-
version time was also correlated with successful 
therapy. Four of 5 (80%) patients with a SCr <3 mg/dl 
had good renal function. while only 7 of 16 (44%) 
patients with a preconverSlon SCr >3 mg/dl had a 
functiomng kidney. The overall SCr pnor to FK506 con-
version In the 11 successful conversions was 3. 70±2. 15 
mg/dl. excluding the SCr of 4 patients who were on 
dialysIs dUring FK506 converSion. The average 
creatinine after the FK506 SWitch was 2.84±1 .40 mg.!dl. 
with all 11 grafts functIOning. 
Primary Therapy 
FK506 was used from the outset with low-dose 
steroids to treat 65 reCipients of pnmary kidney grafts. 
Of the 66 renal allografts transplanted. all but 2 were 
cadaveriC renal allografts: 35% of the 65 recIpients 
were regrafts: 46% of the patients were classified as 
highly senSitized. with a panel reactive antibody (PRA) 
level >40%. Nine percent underwent renal transplanta-
tion In the face of a positive cytotoxIc crossmatch uSing 
current or historical serum samples. Sixteen of the 66 
grafts were pediatric en bloc kidney allografts. 
The actual patient survival posttransplantatlon was 
98%. One diabetic patient With preexisting coronary 
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artery disease died from a postoperative myocardial in-
farction 3 days posttransplantation. The corresponding 
overall graft survival was 79%. In the patients With PRA 
<40%. graft survival was 83%. and in those with PRA 
>40% it was only 73%. Fifty-six percent of patients 
have remained rejection free. The treatment for rejec-
tion episodes was generally accomplished with steroid 
boluses. As a reflection of the ease by which relection 




Ten patients were converted from CsA to FK506 be-
tween 3 and 50 months posttransplant. Persistent heart 
relectlon defined by a >2+ grading of the endomyocar-
dial biopsy by the Billingham criteria (16). included 
mononuclear cell infiltration. artentlS. and. in some in-
stances. Interstitial fibrosis. All patients had failed con-
ventional immunotherapy. Including at least 2 courses 
of antilymphocyte preparations and 2 courses of aug-
mented sterOids during the preceding 6 months. The 
grading of endomyocardial biopSies. pnor to conversion 
to FK506. was 2.7±O.48. Using the same cnteria. the 
mean value of the follow-up biopsies after FK506 was 
graded at 0.7±O.67 (p<0.01). The mean prednisone 
dose prior to FK506 conversion was 14 mg/day. and 
after FK506 conversion this fell to 5.5 mg/day. Only 1 
death occurred during follow-up in a patient With dis-
seminated aspergillosis. 
Primary Therapy 
Following heart transplantation 30 patients received 
FK506 from the outset. Eight patients were on cir-
culatory assist devices prior to heart transplantation. 
Follow-up ranged from 1-10 months. Four patients 
died. With an actual patient and graft survival of 87%. 
One patient with known pulmonary hypertension died 
on the third posttransplant day from nght heart failure. 
One patient with preeXisting lung disease and 
bronchietasls died from pulmonary infection. while 2 
others died suddenly without a known cause. The 
reJection-free rate Within the first 90 days was 60%. 
Only 1 patient reqUired OKT3. Heart function was ex-
celient in all patients. The average left ventncular eJec-
tion fraction. determined by gated nuclear scans or 
echocardiography. was 70% (range 58-75%). 
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Table 1. GvHO following bone marrow 
transplantatIOn treated With FK 506 
(n=11). 
Organ Patients i oes~onse 
Affected Affected ~ Better : Same: Worse I 
Skin 10 7 3 0 I 
Liver 9 7 0 2a 
LunQ 5 1 2 2b 
GI 5 1 4 0 
Musculo-
skeletal 3 0 3 0 
a2 patients required liver transplantation. but died 
following transplantation. 
b1 patient died following liver transplantation with 
GvHD of lung. 1 died from respiratory failure. 
Bone Marrow Transplantation 
Rescue Therapy 
Eleven patients With manifestations of chronic GvHD 
following bone marrow transplantation were placed on 
FK506. Six patients had an original diagnosis of 
chronic myelogenous leukemia. 4 were given bone mar-
row transplants for acute lymphoblastic leukemias. 1 
had aplastic anemia. All grafts were taken from HLA-
identical siblings. All patients were on or had been on 
high doses of GsA and steroids. Table 1 shows the 
organ systems Involved. The most common sites of 
Involvement were skin and liver. followed by lung. GI. 
and musculoskeletal. The most oblectlve parameters to 
evaluate response to FK506 have been those With liver 
and skin Involvement. The mean time after bone mar-
row transplantation to the time of FK506 therapy was 
17.7 months. and the mean follow-up was 3.8 months. 
Of the 9 patients with liver involvement. 5 were 
referred for conSideration for liver transplantation. Two 
of these eventually required liver transplantation. but 
both died; 1 from sepsIs following liver transplantation. 
the other failed to awaken after transplantation having 
been in Stage IV coma pnor to transplantation. One 
other patient died of unknown causes at home, and the 
other 6 patients had a marked response to FK506 res-
cue therapy. In the 10 patients with skin involvement. 7 
improved. while 3 with scleroderma-like involvement 
had stable skin lesions. Two patients with moderate to 
severe obliterative bronchiolitis died from worsening 
lung disease. The remaimng organ system Involvement 
of musculoskeletal and GI tract has not shown progres-
sion dUring FK506 therapy. 
DISCUSSION 
GsA-based immunosuppression slgmficantly en-
hanced both patient and graft survival in all solid organ 
transplants. when compared to the era of Aza and 
sterOids (19). Its use in bone marrow transplantation 
has decreased the incidence and seventy of GvHD 
(20). Nevertheless. most centers experience an unac-
ceptably high complication rate related to ongoing 
GvHD or relection. These immunologically related com-
plications occur in over 70% of all GsA-treated patients. 
In addition. the sequelae of over-immunosuppression in 
attempts to treat rejection or GvHD. such as excessive 
steroids or antilymphocyte preparations. are fraught 
with a high incidence of infectious complications. Logi-
cally, a baseline immunosuppressive agent which al-
lows for less incidence of rejection or GvHD. and easier 
treatment. would decrease both graft and patient loss. 
From the results of our studies presented here. FK506 
treatment In transplantation has these advantages. 
FK506 appears not only to decrease the absolute in-
Cidence of rejection episodes, but makes rejection treat-
ment much simpler. 
The ability of a new Immunosuppressive agent to be 
dose adjustable for treatment of acute rejection. chronic 
rejection, or GvHD, would represent an important asset. 
which in the past has only been ascribed to steroids. 
FK506 can be used in this manner. In fact, the first 
response to a developing rejection is to Increase the 
dose of baseline FK506. In rescue therapy, the marked 
ability of FK506 to reverse acute relection In kidney and 
heart relectlon, acute and chromc rejection In liver 
transplantation, and chrOniC GvHD in bone marrow 
transplantation. has not been seen With any other im-
munosuppressive agent. Whereas the mechanism by 
which FK506 is able to accomplish this IS unknown, It 
appears that it would include mechanisms other than 
simply inhibition of IL-2 syntheSis. 
Prospective, randomized trials comparing FK506 
therapy With GsA-based immunosuppression are cur-
rently underway. The preliminary results in liver 
transplantation at the University of Pittsburgh are en-
couraging. Multicenter tnals are also underway. and 
preliminary reports are also encouraging. A well-
defined endpOint. other than palient or graft loss, should 
be utilized, since the data presented here also suggest 
that a conversion to FK506 Will allow endangered al-
lografts to be salvaged. Other randomized trials in kin-
dey, heart. and bone marrow transplantatIOn will await 
the results of the liver trials. 
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SUMMARY 
FK506 IS a potent Immunosuppressive agent 
which is undergoing clinical testing In liver. kidney. 
heart. and bone marrow transplantation. It has been 
shown to effectively prevent and reverse ongoing 
rejection In these models. From the outset. FK506 
was used with low-dose sterOids to treat 11 0 primary 
liver. 30 heart. and 66 kidney graft recipients. FK506 
was also used In the setting of complications related 
to GsA or to ongoing chronic or acute rejection. One 
hundred seventy-three liver. 21 kidney. 10 heart. and 
11 bone marrow reCipients were converted to FK506 
and low-aose steroids. from a combination of GsA. 
steroids. and/or Aza. A randomized. prospective trial 
comparing FK506 with GsA in pnmary liver transplan-
tation has verified the lower inCidence of rejection 
and greater ease In treating rejection episodes. with 
fewer adverse effects. In summary. FK506 has 
proven to be an effective baseline immunosuppres-
sive agent. as well as a dose-adjustable agent for the 
treatment of rejection. 
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